You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search

Metabolic Complications
Cardiovascular Disease / Cholesterol
Triglycerides / Diabetes / Insulin Resistance / Hyperlipidemia / Myocardial Infarction

More Evidence Abacavir Does Not Raise Heart Attack Risk
4-18-2011

Risk of Strokes Is Increasing for People with HIV
1-28-2011

Elevated Triglyceride Level Increases Likelihood of Peripheral Neuropathy
1-11-2011

Effectiveness of Statins among HIV Positive People on Antiretroviral Therapy
1-11-2011

HIV Infection Linked to Increased Cardiovascular Risk Even in Long-term Non-progressors
9-17-2010

Traditional Risk Factors Predict Cardiovascular Risk in People with HIV
8-31-2010

HIV Positive People Could Benefit from Aspirin to Reduce Cardiovascular Risk
8-31-2010

METABOLIK (Metabolic Evaluation in Treatment-na´ves Assessing the impact of two Boosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks
7-23-2010

Darunavir/ritonavir increases rosuvastatin concentrations but does not alter lipid lowering effect in healthy volunteers
7-09-2010

Late Antiretroviral Therapy Raises Risk of Early Atherosclerosis
7-09-2010

Pentoxifylline May Improve Endothelial Dysfunction in People with HIV
7-09-2010

Niacin May Improve Blood Vessel Function in People with HIV

5-25-2010

Cholesterol Crystals Trigger Inflammation Leading to Atherosclerosis
5-25-2010

People with HIV Often Have Elevated Homocysteine Levels during Antiretroviral Treatment
4-27-2010

Switching to Atazanavir (Reyataz) Lowers Cholesterol and Triglycerides, but No Improvement in Artery Function
4-6-2010

Heavy Alcohol Use Increases Risk of Cardiovascular Disease in Men with HIV
4-2-2010

Metabolic Profiles and Body Composition Changes in Treatment-Na´ve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up

2-23-2010

Body Composition and Metabolic Changes in the SMART Treatment Interruption Trial
2-16-2010


Progestin-only Hormonal Contraception Linked to Lower HDL Levels and More Insulin Resistance in Women with HIV
1-19-2010

Some Antiretroviral Drugs Linked to Heart Attacks in D:A:D Study, but Overall Risk Remains Small
1-15-2010

HIV Positive Men Have More Atherosclerosis and Higher Vascular Age than Uninfected Men
1-15-2010

Persistent Detectable HIV Viral Load Is Linked to Metabolic Syndrome
12/11/09

Traditional Cardiovascular Risk Factors Strongly Predict Likelihood of Myocardial Infarction in People with HIV
12/01/09

Effective Antiretroviral Therapy Leads to Improved Lung Function in People with HIV
10/09/09

HIV Infection Sharply Increases Risk of Atherosclerosis, but Antiretroviral Therapy Has a Minor Effect
9/11/09

Artery Elasticity Is Reduced in People with Untreated HIV Infection
9/11/09


Confounding Factors May Explain Elevated Cardiovascular Risk in Patients Taking Abacavir
7/28/09

Nevirapine (Viramune) Has Equal Efficacy but a More Favorable Lipid Profile Compared with Boosted Atazanavir (Reyataz)
7/28/09

Intensive Cardiovascular Intervention Lowers Blood Lipids in HIV Patients on Antiretroviral Therapy
7/24/09

Switching from Lopinavir/ritonavir (Kaletra) to Boosted Atazanavir (Reyataz) Reduces Visceral Fat and Improves Glucose Metabolism
7/10/09

Ongoing HIV Replication during Treatment Interruption Is Associated with Inflammatory and Cardiovascular Risk Markers
6/5/09

GlaxoSmithKline Meta-analysis Does Not Show Elevated Cardiovascular Risk Associated with Use of abacavir (Ziagen, Epzicom)
5/19/09

Metabolic and Body Shape Abnormalities Are Common in Children and Youth with HIV
5/15/09

Natural Hormone Leptin Improves Blood Lipid Levels and Insulin Sensitivity and Decreases Abdominal Fat in People with HIV
5/08/09

Study Shows High Prevalence of Metabolic Syndrome and Associated Cardiovascular Risk in Older HIV Patients
1/13/09

Ezetimibe (Zetia) Reduces Bad LDL Cholesterol in HIV Positive People on HAART
10/17/08


Blood Lipid Profiles Improve after CD4-guided Treatment Interruption
9/25/08

SMART Researchers Publish Findings Showing Abacavir (Ziagen) Is Associated with Elevated Risk of Cardiovascular Disease
9/09/2008

Management of Elevated Blood Lipids May Be Less Successful in HIV Patients with High Cardiovascular Risk
9/09/2008

Does Raltegravir (Isentress) Worsen Depression in HIV Patients with a History of Treatment for Depression?
9/05/08

Levels of Osteopontin Protein Are Elevated in People with HIV-associated Dementia
9/05/08

FDA Announces Changes to Ritonavir (Norvir) Label to Reflect New Data on Heart Rhythm Abnormalities
9/05/08

Coronary Heart Disease, HIV Infection, and Antiretroviral Therapy
8/22/08


Studies Look at Association between CD4 Cell Count and Cardiovascular Risk in People with HIV
8/22/08

Does Abacavir (Ziagen) Raise Heart Attack Risk? Conflicting Answers from SMART and 54-study Pooled Analysis
8/12/08

Does Abacavir (Ziagen) Raise Heart Attack Risk? Conflicting Answers from SMART and 54-study Pooled Analysis
8/12/08

Experts Recommend Cardiovascular Risk Screening for People with HIV
7/08/08


HIV Positive Children and Adolescents Have Elevated Risk of Cardiovascular Disease
7/08/08


Studies Find Minimal Cardiovascular Benefit and Increased Mortality with Intensive Glucose Management for People with Type 2 Diabetes
6/20/08

High-density Lipoprotein (HDL) Cholesterol in People with HIV: Association with Viral Load and Antiretroviral Therapy
6/03/08


Ezetimibe Combined with Low-dose Statin Drugs Effectively Reduces Low Density Lipoprotein (LDL) in HIV Patients on Protease Inhibitors
6/03/08


Controlling Cholesterol with Statins
5/23/08


Does Tenofovir (Viread) Increase Liver Toxicity Related to Efavirenz (Sustiva)?
5/16/08

Body Fat and Blood Lipid Levels in Men and Women with HIV
5/16/08

Body Shape Changes
in HIV Positive and HIV Negative Women
5/16/08

Worsening Cardiovascular Risk among HIV Positive Individuals in D:A:D Study Has Not Led to an Increase in Heart Attacks
5/13/08

Interaction between Lopinavir-ritonavir (Kaletra) and Rosuvastatin (Crestor) Reduces Drug's Lipid-lowering Effect
5/13/08


Persistent AIDS-related Kaposi Sarcoma in the HAART Era Reveals Need for New Therapies
5/09/08



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children